NA
SGMT icon

NewEdge Advisors’s Sagimet Biosciences SGMT Stock Holding History

NewEdge Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,070
Closed -$5.59K – 4361
2026
Q1 		$5.59K Buy
+1,070
New +$5.96K ﹤0.01% 3559
2025
Q2 		– Sell
-32,290
Closed -$105K – 4134
2025
Q1 		$105K Buy
+32,290
New +$135K ﹤0.01% 2279

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

NewEdge Advisors's SGMT Position: Q2 2026 in Review

NewEdge Advisors sold out of Sagimet Biosciences (SGMT) in Q2 2026, closing a stake of 1,070 shares — an estimated $5.59K sold.

NewEdge Advisors first reported a position in SGMT in Q1 2025 and held it in 2 quarters. The position peaked at $105K in Q1 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • NewEdge Advisors reported no remaining Sagimet Biosciences position as of Q2 2026 after selling out during the quarter.
  • NewEdge Advisors sold 1,070 Sagimet Biosciences shares in Q2 2026, an estimated $5.59K.
  • NewEdge Advisors first reported a position in Sagimet Biosciences in Q1 2025 and held it in 2 quarters.
  • NewEdge Advisors's Sagimet Biosciences position peaked at $105K in Q1 2025.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.